Experimental thrombosis I: Relation with fibrinogen and other haemostatic parameters

Thrombosis Research

Volumn 99, Issue 3, 2000, Pages 295-305

  Hernández, Luis R González ^a   Lundberg, Ulf ^a   Arocha Piñango, Carmen Luisa ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Atherosclerosos; Experimental atheroma; Hemostatic parameters; Hypercholesterolemia; Rabbits

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HEMATOCRIT; HEMOSTASIS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; DIET, ATHEROGENIC; FERRITINS; FIBRINOGEN; HEMATOCRIT; HEMOSTASIS; HYPERCHOLESTEROLEMIA; LEUKOCYTE COUNT; RABBITS; RISK FACTORS; THROMBOMODULIN; THROMBOSIS; TRIGLYCERIDES; TUNICA INTIMA; VON WILLEBRAND FACTOR;

EID: 0034209673     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00239-5     Document Type: Article

References (71)

1. Eliasson M., Ervin P.E., Lundblad D. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. A population study. Fibrinolysis. 7:1993;316-323.
2. Jern C.Y., Eriksson E., Tengborn L. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost. 62:1989;767-771.
3. Witterman J.C.M., Grobbee D.E., Valkenburg H.A., van Hemert A.M., Stijnen T., Hofman A. Cigarrete smoking and the development and progression of aortic atherosclerosis. Circulation. 88:1993;2156-2162.
4. Laakso M., Kuusisto J. Epidemiological evidence for the association of hyperglycemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med. 28:1996;415-418.
5. Carman W.J., Barret-Connor E., Sowers M.F. Higher risk of cardiovascular mortality among hypertensive individuals in Tecumseh, Michigan. Circulation. 89:1994;703-711.
6. Cook N.S., Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. TIPS. 11:1990;444-451.
7. Ernst E., Resch C.L. Fibrinogen as a cardiovascular risk factor. a meta-analysis and review of the literature Ann Int Med. 118:1993;956-963.
8. Arocha-Piñango C.L., Nagy E., Mijares M.E., Velásquez L., Espinosa R., Cova A. Relación de fibrinógeno (Fg) y otros parámetros hemostáticos con eventos cardiovasculares isquémicos (ECI). Revisión de la literatura. Rev Iberoamer. Tromb. Hemost. 8:1995;183-191.
9. Caen J.P., Soria J., Collet P., Soria C. Le Fibrinogène un facteur de risque vasculaire. Bull Acad Natl Med. 177(8):1993;1433-1444.
10. Meade TW, Brozovic M, Chakrabarti R, Haines AP, Imeson JD, Mellows S, Miller GJ, North GJ, Stirling I, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Nortwick Park Heart Study. Lancet 1988;533-7.
11. Yarnell J.W.G., Baker I.A., Sweetnam P.M., Bainton D., O'Brien J.R., Whitehead P.J., Elwood P.C. Fibrinogen, viscosity, and white blood cell count are major risk factor for ischemic heart disease. The Caerphilly and Speedwell Colaborative Heart Disease Studies. Circulation. 83(3):1991;836-844.
12. Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., van de Loo J.C.W. Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris. N Engl J Med. 332:1995;635-641.
13. Di Minno G., Mancini M. Measuring plasma fibrinogen to predict myocardial infarction. Arteriosclerosis. 10:1990;1-7.
14. Maresca G., Di Blasio A., Marchioli R., Di Minno G. Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. Arterioscler Thromb Vasc Biol. 19:1999;1368-1377.
15. Ross R. The pathogenesis of atherosclerosis. An update. N Engl J Med. 314:1986;488-500.
16. Ross R. Atherosclerosis - an inflamatory disease. N Engl J Med. 340:1999;115-125.
17. Steinberg D. Lipoproteins and Atherosclerosis. A look back and look ahead. Arteriosclerosis. 3:1983;283-301.
18. Badimon L, Royo T, Alpon J, Berrozpe M, Badimón JJ. Patophysiology of atherosclerosis and thrombosis. In: Lectures 15th International Congress on Thrombosis. ON Ulutin (Ed). Meta Basin Yayim, Sanayi Ticaret Istanbul, 1998. Pp. 73-80.
19. Smith E., Kee A., Grant A., Strik C. Fate of fibrinogen in human arterial intima. Arteriosclerosis. 10:1990;263-275.
20. Mosesson M.W. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Seminars Thromb Haemost. 19:1993;104-109.
21. Koening E., Ernst E. The possible role of hemorheology in atherothrombogenesis. Artherosclerosis. 84:1992;93-107.
22. Meade T.W., Viekers M.V., Thomson S.G., Stirling F., Haines H.P., Miller G.J. Epidemiological characteristics of platelet aggregability. Br Med J. 290:1985;428-432.
23. Naito M., Hayashi T., Kuzuya M., Funaky C., Asai K., Kuzuya F. Fibrinogen is chemotactic for vascular smooth muscle cells. FEBS. 247:1989;358-360.
24. Tanaka K., Sueishi K. Biology of Disease. The coagulation and fibrinolysis systems and atherosclerosis. Lab Invest. 69:1993;5-18.
25. Blombäck B, Banerjee D, Carlsson K. Native Fibrin Gel Networks and Factors Influencing their formation in health and disease. In: Liu CY, Chian S, editors. Fibrinogen, Thrombosis, Coagulation and Fibrinolysis. Advances in Experimental Medicine and Biology. Pergamon Press, 1990. pp. 1-23.
26. Blum A., Miller H. The role of inflammation in Atherosclerosis. J Int Med. 258:1996;479-489.
27. Vasse M., Collet J.P., Soria J., Mirshahi S.S., Vannier J.P., Soria C. Fibrinógen a vascular risk factor. A simple marker or a real cause of vascular lesion? Thromb Res. 75:1994;349-352.
28. Copley A.L. Fibrinogen, platelets and a new theory of atherosclerosis. Thromb Res. 14:1979;249-258.
29. Seghatchian MJ, Halle AA, McKiernan T, Jhonson S, Favid S, Messmore JV. Von Willebrand factor in thrombotic disorders. In: Seghatchian MJ, Samama MM, Hecker SP, editors. Hypercoagulable states. Fundamental aspects, acquired disorders, and congenital thrombophillia. Diagnostica Stago. CRC Press Inc., 1996. pp. 101-4.
30. Jansson J.H., Tarbjorn K.N., Johnson O. Von Willebrand factor in plasma. a novel risk factor for recurrent myocardial infarction and death Br Heart J. 66:1991;351-356.
31. Badimon L., Badimon J.J., Chesebro J.H., Fuster V. Von Willebrand factor and cardiovascular disease. Thromb Haemost. 70:1993;111-118.
32. Nichols T.C., Bellinger D.A., Tate D.A., Reddiek M.S., Koch G., Brinkhous K.M., Griggs R.T. Von Willebrand factor and occlusive arterial thrombosis. a study in normal and von Willebrand's disease pigs with diet induced hypercholesterolemia and arteriosclerosis Arteriosclerosis. 10:1990;449-461.
33. Pottinger B.E., Read R.C., Paleolog E.M., Higgins P.G., Pearson J.D. Von Willebrand factor is an acute phase reactant in man. Thromb Res. 53:1988;387-394.
34. Takano S., Kimura S., Ohdama S., Aoki N. Plasma thrombomodulin in health and diseases. Blood. 76:1990;2024-2029.
35. Seigneur M., Dufourcq P., Conri C., Constans J. MerciJ P, Pruvost A, Amiral J, Midy D, Baste J-C, Boisseau MR. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res. 71:1993;423-431.
36. Ihara A., Furubayashi Y., Kabayasi T., Kawamoto T., Yoshino T., Ishikawa K., Tanogochi T., Fujimura K., Kuramoto A. Plasma levels of soluble thrombomodulin in patients with ischemic heart disease. Thromb Haemost. 69:1993;739. (Abstract).
37. Naruse M., Kawana M., Hifumi S., Naruse K., Yoshihara I., Oka T., Kato Y., Monzen C., Kurimoto F., Ohsuni K., Hosoda S., Demura H. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essentials hypertension and ischemic heart disease. J Cardiovasc Pharmacol. 17:1991;471-474.
38. Salonen J., Nyysönen K., Korpela H., Tuomilehto J., Seppänen R., Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern finnish men. Circulation. 86:1992;803-811.
39. Araujo J.A., Romano E.L., Brito B.E., Parthe V., Romano M., Bracho M., Montaño R.F., Cardier J. Iron overload augments the development of atherosclerosis lesions in rabbits. Arterios Thromb Vasc Biology. 15:1995;1172-1180.
40. Edwards R.L., Rickles F. The role of leukocytes in the activation of blood coagulation. Seminars in Hematology. 29:1992;202-212.
41. Grice H.C. Methods for obtaining blood and for intravenous injection in laboratory animals. Laboratory animal care. 14:1964;483-493.
42. Bowman R.E., Wolf R.C. A rapid and specific ultramicro metod for total serum cholesterol. Clin Chem. 8:1962;302-309.
43. Biggs H.G., Erikson J.M., Moorehead W.R. A manual cholorimetric assay of triglyceriddes in serum. Clin Chem. 21:1975;437-441.
44. Ingram G.I.C. The determination of plasma fibrinogen by the clot - weight method. Biochem J. 51:1952;583-585.
45. Laurell C.B. Antigen-antibody crossed electrophoresis. Ann Biochem. 10:1965;358-361.
46. Preparation, characterization, and storage of human ferritin for use as standard for the assay of serum ferritin. Clin Lab Haematol. 6:1984;177-191.
47. Willis A.L., Nagel B., Churchill V., Whyte M.A., Smith D.L. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis. 5:1985;250-255.
48. Dorsett B.H., Ioachim H.L. A method for the use of immunofluorescence on paraffin-embedded tissues. Amer J Clin Pathol. 69:1978;66-72.
49. Johnstone A, Thorpe R. Immunochemistry in practice, Second edition. Boston: Blackwell Scientific Publications, 1987.
50. Siegel S. Nonparametric Statistics for the Behaviorial Sciences. 1956;MacGraw Hill Book Company, New York.
51. Astrup T., Brakman P., Nissen U. The estimation of fibrinogen. A Revision. Scand J Clin Lab Invest. 17:1965;57-65.
52. Jacobsson K. Studies in the determination of fibrinogen in human blood plasma. Scand J Clin Lab Invest. 7(suppl 14):1955;9-13.
53. De Maat MPM, Haverkate F. Critical evaluation of fibrinogen assays. In: Seghatchian MJ, Samama MM, Hecker SP, editors. Hypercoagulable states, fundamental aspects, acquired disorders, and congenital thrombophilia. Diagnostica Stago CRC Press Inc. 1996. pp. 105-15.
54. Kritchevsk D., Tepper S.A., Bisses G., Klurfeld D.M. Experimental atherosclerosis. Atherosclerosis in rabbit fed cholesterol-free diets. Atherosclerosis. 41:1982;279-284.
55. Armstrong M.L., Herstad D.D. Animals models of atherosclerosis. Atherosclerosis. 85:1990;15-23.
56. Richardson M., Kurowsca E.M., Carroll K.K. Early lesion development in aortas on rabbits fed low-fat, cholesterol-free, semipurified casein diet. Atherosclerosis. 107:1994;165-178.
57. Merskey C., Wahl H. Changes in blood coagulation and fibrinolysis in rats fed atherogenic diets. Thromb Diath Haemorrh. 10:1964;295-308.
58. Brito B. Estudio del Factor de necrosis tumoral en conejos hipercolesterolemicos. PhD Thesis. Caracas: Instituto Venezolano de Investigaciones Científicas; 1994.
59. Simpson H.C.R., Mann J.I., Meade T.W., Chakrabati R., Stirling Y., Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet. 1:1983;786-790.
60. Ruggeri Z.M., Ware J.L., Ginsburg D. von Willebrand factor. Lozcalo J., Schafer A.I. Thrombosis and Hemorrhage. 1994;305-329 Blackwell Scientific Publications, Boston.
61. Kiechl S., Aichner F., Gerstenbrand F., Egger G., Mair A., Rungger G., Spögler F., Jordash E., Oberhollenzer F., Willeit J. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck study. Arterios Thromb. 14:1994;1625-1630.
62. McKenzie S.B. Text Book of Hematology. 1988;Lea & Febiger, Philadelphia.
63. Arocha-Piñango C.L. El fibrinógeno. su relación con la enfermedad arterial coronaria. Resultados preliminares de un estudio multicéntrico Rev Chil Cardiol. 15:1996;66-77.
64. Friedman G.D., Klatsky A.L., Siegelaub A.B. The leukocyte count as a predictor of myocardial infarction. N Engl Med J. 290:1974;1275-1278.
65. Chemnitz J., Christensen B.C. Repair in arterial tissue. Demonstration of fibrinogen-fibrin in the normal and healing rabbit thoracic aorta by the indirect immunoperoxidase technique. Virchows Arch Pathol Anat. 403:1984;163-171.
66. Crawford T., Levine C.I. The incorporation of fibrin within the aortic intima. J Path Bact. 64:1952;523-528.
67. Bini A., Fenoglio J.J., Mesa-Tejada R., Kudryk B., Kaplan K.L. Identification and distribution of fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis. 9:1989;109-121.
68. Woolf N. The distribution of fibrin within the aortic intima. An immunohistochemical study. Am J Path. 39:1961;521-532.
69. Haust M.D., Wyllie J.C., More R.H. Atherogenesis and plasma constituents. I Demonstration of fibrin on the white plaque by the fluorescent antibody technique. Am J Path. 44:1964;255-261.
70. Zhang Y., Cliff W.J., Shoefl G.I., Higgins G. Immunohistochemical study of animal microvessels in coronary atherosclerosis. Am J Pathol. 143:1993;164-172.
71. Smith E.B., Thompson W.D. Fibrin as a factor in atherogenesis. Thromb Res. 73:1994;1-19.